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Background
Several findings from the basic sciences, show the involve-
ment of the membrane phospholipids in brain function-
ing. In particular, they are directly involved in all signal
transduction cascades and the overall function of all the
membrane-bound and membrane-associated proteins.
The essentiality of the essntial polyunsaturated fatty acids
(EPUFAs) has been established since 1929 by Burr and
Burr. There are two types of them: omega-3 and omega-6,
so named for the position of carbon double bonds in the
chain. The principal CNS EPUFAs are: eicosapntaenoic
acid (EPA) and docosahexaenoic acid (DHA), both
omega-3, and arachidonic acid (AA), which is omega-6.
Extensive work has shown that AA and DHA metabolism
is altered in the very early stages in schizophrenia.
Reduced membrane PUFAs have been linked with symp-
tom severity and development of tardive dyskinesia. All
the findings taken together support the notion that the
molecular changes in membrane phospholipds may be
present prior to both clinical and biological manifesta-
tions of the disorder. Most studies suggest that both AA
and DHA are critically involved in the pathophysiology of
schizophrenia, as dietary depletin of them on the foetus,
in animal studies, has resulted in significant morphologi-
cal abnormalities in brain regions, which are also
involved in the pathophysiology of schizophrenia.The
same studies point at a significant involvement of AA and
DHA in the pathophysiology of the disorder. The modern
Western diet has changed into a meat and saturated fat
one, with asignificant rise in the consumption of seed oils
(such as sunflower and soybean), whose PUFA content
imainly omega-6 at the expense of omega-3 (the former
have much more inflammatory effects than the latter).
The omega-6 to omega-3 ratio was 0.4–2.8:1 in the Palae-
olithic and evolutionary diets, but today, especially in the
second half of the 20th century, this ratio has risen to
17:1. EPUFAs are also susceptible to peroxidation, which
in turn is associated with schizophrenia and compounded
by a number of factors, such as the unhealthy lifestyle of
the patients with the disorder. Taking all the above into
account, it has been proposed that schizophrenia is a
membrane lipid disorder that is expressed throughout the
body and although the validity of the hypothesis remains
unknown, it has been shown beyond doubt, using a vari-
ety of methods (including MRS), bith in vivo and post-
mortem, that there are significant alterations of the phos-
pholipids' biochemistry in the brains and the rest of the
body of patients with the disorder. Currently, significant
work is under way in the form of measuring the therapeu-
tic effect of interventions aiming to restore the abnormal-
ity, involving both pharmacological inerventions and
lifestyle changes.
Materials and methods
We studied and evaluated all the clinical trials (there are
now five published placebo controlled double blind trials
of eicosapentaenoic acid [EPA] in scizophrenia), open
label studies and theories, targeting the membrane phos-
pholipids to date. We compared the results and how the
findings from the basic research could guide for nove
intrventions
Results
Four out of five placebo-controlled double blind trials
with EPA have shown positive results, but the evidence is
rather suggestive than definitive as larger scale trials are
needed. At present, the most promising approach is the
use of ethyl-EPA at the dose of 2 g. The difference in meth-
odology in the studies is a confounding factor, so this
among other issues needs to be amended. Overall the evi-
dence suggests that the hypothesis has substantial founda-
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tions but more interventional options as well as larger
scale studies with the existing ones are worth pursuing.
Discussion
The evidence so far points to a definite membrane phos-
pholipid abnormality in schizophrenia. As more details
are revealed by the basic research a more comprehensive
theoretical basis is formed, which will enable the design
of clinically usefull interventions in this direction. The evi-
dence so far though suggests that every effort by the means
of lifestyle (diet is a part of it) change in order to rectify the
membrane lipd abnormality is worth trying along the
usuall pharmacological inerventions, but more work is
needed in both the basic research and clinical levels in
order to design succesfull inerventions, following the cen-
tral theme of therapeutics: "From the bench-to-the bed-
side"
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